Manufacturer record

CMG Biotech Pvt. Ltd: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

15 batches manufactured by CMG Biotech Pvt. Ltd (Himachal Pradesh) were declared Not of Standard Quality between March 2019 and June 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

15 records linked to CMG Biotech Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
15Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Mar 2019 to Jun 2026

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

15
NSQ batches since 2019
13
Products affected
Assay
Most common failure
Jun 2026
Latest alert

Flagged batches per year

2019 · 12022 · 12023 · 22024 · 42025 · 52026 · 2

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Furosemide & Spironolactone Tablets CT24251187BMfg 2024-10 · Exp 2026-09 Description as per Schedule V of Drugs and Cosmetics act 1940 & Rules 1945 thereunder.Description DTL, Bengaluru, KarnatakaState lab Jun 2026
Pre & Probiotic Capsules CC25260109AMfg 2025-08 · Exp 2027-01 The sample does not conform to claim with respect to the identification of Clostridium butyricum and Assay of Clostridium butyricum,Assay CDL, KolkataCDSCO lab Mar 2026
Atorvastatin Tablets IP 20mg CT24250048Mfg 2024-04 · Exp 2026-03 Assay and Dissolution testAssay SDT&RL, BhubaneswarState lab Dec 2025
Valsartan Tablets IP CT24250295Mfg 2024-05 · Exp 2026-04 DissolutionDissolution CDTL, IndoreCDSCO lab Jul 2025
Doxepin Hydrochloride Capsules IP (Doxon 75) CC23240161Mfg 2024-02 · Exp 2026-01 Dissolution and Assay of Doxepin Hydrochloride.Assay CDL, KolkataCDSCO lab Jul 2025
Betahistine Dihydrochloride Tablet I.P (CGHEST-8) CT24250284AMfg 2024-05 · Exp 2026-04 DescriptionDescription CDTL- IndoreCDSCO lab May 2025
Atorvastatin Tablets IP (GATOVAS- 20) CT24250423Mfg 2024-06 · Exp 2026-05 "Related substances"Related substances CDTL-MumbaiCDSCO lab Mar 2025
Fexofenadine Hydrochloride Tablets IP (MANOFEX-180 ) CT24250327 AMfg 2024-05 · Exp 2026-04 DissolutionDissolution CDL KolkataCDSCO lab Dec 2024
Ciprofloxcin Tablets IP 250 mg CT23241818Mfg 2024-02 · Exp 2026-01 Dissolution of CiprofloxcinDissolution RDTL GuwahatiCDSCO lab Oct 2024
BETAHISTINE DIHYDROCHLO RIDE TABLETS IP(CGHEST-8) CT2425028 4BMfg 2024-03 · Exp 2026-04 On the received sample presence of spots were observed which should not be present As per DCC Guidelines on Not Of Standard Quality (NSQ) Drugs Approved in 1993 (Annexure A) Tablets vide serial No.(i) Presence of Spot/discolouration-NSQDescription State Lab PuducherryState lab Oct 2024
Fexofenadine Hydrochloride Tablets IP (MANOFEX-180 TABLETS) CT232407 15AMfg 2023-08 · Exp 2025-07 Dissolution (In 10 minutes) and (in 30 minutes)Dissolution RDTL ChandigarhCDSCO lab Jun 2024
Manokast 5 (Montelukast Tablets IP) CT22230271AMfg 2022-05 · Exp 2024-04 Assay of MontelukastAssay CDL KolkataCDSCO lab Jun 2023
CGTROM-1 (Nicoumalone Tablets IP) CT22231818Mfg 2023-03 · Exp 2025-02 Related substancesRelated substances CDL KolkataCDSCO lab Jun 2023
Gatoline-100 (Doxycycline Capsules I.P.) CC-200140Mfg 2020-12 · Exp 2022-11 AssayAssay CDL KolkataCDSCO lab Mar 2022
Sodium Alendronate Tablets (GATOFOS- 35 TABLETS) CT-017893Mfg 2018-03 · Exp 2020-02 Assay of Sodium Alendronate calculated as Alendronic AcidAssay RDTL ChandigarhCDSCO lab Mar 2019

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.